NASDAQ:INO

Inovio Pharmaceuticals Stock Forecast, Price & News

$8.61
+0.02 (+0.23 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.44
$8.69
50-Day Range
$7.37
$10.03
52-Week Range
$5.81
$22.13
Volume2.88 million shs
Average Volume3.50 million shs
Market Capitalization$1.80 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.64
30 days | 90 days | 365 days | Advanced Chart
Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Inovio Pharmaceuticals logo

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

658th out of 1,309 stocks

Surgical & Medical Instruments Industry

71st out of 121 stocks

Analyst Opinion: 3.1Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

Is Inovio Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Inovio Pharmaceuticals?

Wall Street analysts have given Inovio Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inovio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Inovio Pharmaceuticals
.

How can I listen to Inovio Pharmaceuticals' earnings call?

Inovio Pharmaceuticals will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.09. The biopharmaceutical company earned $0.40 million during the quarter, compared to the consensus estimate of $1.06 million. Inovio Pharmaceuticals had a negative net margin of 2,916.64% and a negative trailing twelve-month return on equity of 39.16%. The business's revenue was down 69.2% on a year-over-year basis.
View Inovio Pharmaceuticals' earnings history
.

How has Inovio Pharmaceuticals' stock been impacted by Coronavirus?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INO stock has increased by 2.9% and is now trading at $8.61.
View which stocks have been most impacted by COVID-19
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

9 analysts have issued 1-year price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $6.00 to $35.00. On average, they expect Inovio Pharmaceuticals' share price to reach $14.89 in the next twelve months. This suggests a possible upside of 72.9% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 52, Pay $1.21M)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 58, Pay $653.91k)
  • Dr. Jacqueline E. Shea Ph.D., Chief Operating Officer (Age 55, Pay $637.32k)
  • Dr. Laurent M. Humeau, Chief Scientific Officer (Age 54, Pay $637.37k)
  • Ben Matone, Director of Investor Relations
  • Mr. E. J. Brandreth, Sr. VP of Quality Assurance
  • Ms. Jessica C. Lee MS, MPH, Sr. VP of Clinical Operations & Global Integration
  • Dr. Ami Shah Brown, Sr. VP of Regulatory Affairs
  • Dr. Jeffrey Skolnik, Sr. VP of Clinical Devel.
  • Mr. Robert J. Juba Jr., Sr. VP of Biological Manufacturing & Clinical Supply Management

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.15%), New York State Common Retirement Fund (0.09%), Advisor Group Holdings Inc. (0.07%), Defender Capital LLC. (0.06%), Green Alpha Advisors LLC (0.03%) and Arizona State Retirement System (0.03%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals
.

Which major investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Equitec Specialists LLC, Arizona State Retirement System, Zurcher Kantonalbank Zurich Cantonalbank , and Victory Capital Management Inc.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies, and Simon X Benito.
View insider buying and selling activity for Inovio Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Green Alpha Advisors LLC, New York State Common Retirement Fund, Oppenheimer & Co. Inc., Advisor Group Holdings Inc., IFP Advisors Inc, Defender Capital LLC., and Paragon Wealth Strategies LLC. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau.
View insider buying and selling activity for Inovio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $8.61.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals has a market capitalization of $1.80 billion and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166,410,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 262 workers across the globe.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

Where are Inovio Pharmaceuticals' headquarters?

Inovio Pharmaceuticals is headquartered at 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 858-410-3134 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.